- Home
- RLGT vs FDMT Comparison
RLGT vs FDMT Comparison
Compare RLGT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLGT | FDMT |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.1M | 449.6M |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RLGT | FDMT |
|---|---|---|
| Price | $9.29 | $11.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $8.00 | ★ $31.71 |
| AVG Volume (30 Days) | 137.6K | ★ 875.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.75 | 18.79 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $902,696,000.00 | $85,209,000.00 |
| Revenue This Year | $2.13 | N/A |
| Revenue Next Year | $5.18 | $70.28 |
| P/E Ratio | $39.83 | ★ N/A |
| Revenue Growth | 12.49 | ★ 230194.60 |
| 52 Week Low | $5.78 | $3.68 |
| 52 Week High | $9.45 | $12.34 |
Technical Indicators
Market Signals| Indicator | RLGT | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 62.90 |
| Support Level | $8.68 | $8.39 |
| Resistance Level | $9.45 | $11.85 |
| Average True Range (ATR) | 0.31 | 0.83 |
| MACD | 0.00 | 0.29 |
| Stochastic Oscillator | 75.16 | 74.54 |
Price Performance
Historical ComparisonAbout RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).